Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease

被引:44
作者
Haas, Stefan Jean-Pierre [1 ]
Zhou, Xiaolai [2 ,3 ]
Machado, Venissa [2 ,4 ,5 ]
Wree, Andreas [1 ]
Krieglstein, Kerstin [4 ]
Spittau, Bjoern [4 ]
机构
[1] Univ Rostock, Med Ctr, Inst Anat, D-18055 Rostock, Germany
[2] Univ Freiburg, Inst Anat & Cell Biol, Dept Mol Embryol, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Mol Biol & Genet, Ithaca, NY USA
[4] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Hugstetter Str 55, D-79106 Freiburg, Germany
[5] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany
关键词
6-OHDA; microglia; astrocytes; Tnfu; Tgf beta 1; GROWTH-FACTOR BETA-1; MICROGLIAL ACTIVATION; TIME-COURSE; 6-OHDA; SYSTEM; CELLS; NEURONS; NG2; MACROPHAGES; ASTROCYTES;
D O I
10.3389/fnmol.2016.00007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microgliamediated neuroinflammation has been described as a common hallmark of PD and is believed to further trigger the progression of neurodegenerative events. Injections of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA neurons in rodents as an attempt to mimic PD and to study neurodegeneration, neuroinflammation as well as potential therapeutic approaches. In the present study, we addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu) after 6-0HDA injections into the medial forebrain bundle (MFB), and further analyzed the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory markers in this mouse model of PD. We provide evidence that activated microglia as well as neurons in the lesioned SN and CPu express Transforming growth factor beta 1 (Tgf beta 1), which overlaps with the downregulation of pro-inflammatory markers Tnfu, and iNos, and upregulation of anti-inflammatory markers Yrn /and Argl. Taken together, the data presented in this study suggest an important role for Tgf beta 1 as a lesion-associated factor that might be involved in regulating microglia activation states in the 6-OHDA mouse model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated release of neurotoxic factors such as Info and nitric oxide (NO).
引用
收藏
页数:14
相关论文
共 50 条
[41]   TNFR1-mediated neuroinflammation is necessary for respiratory deficits observed in 6-hydroxydopamine mouse model of Parkinsons Disease [J].
Cabral, Lais M. ;
Oliveira, Luiz M. ;
Miranda, Nicole C. ;
Kawamoto, Elisa M. ;
Costa, Soraia K. P. ;
Moreira, Thiago S. ;
Takakura, Ana C. .
BRAIN RESEARCH, 2024, 1822
[42]   Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease [J].
Zhou, Ming ;
Zhang, Wangming ;
Chang, Jingyu ;
Wang, Jun ;
Zheng, Weixin ;
Yang, Yong ;
Wen, Peng ;
Li, Min ;
Xiao, Hu .
NEUROSCIENCE LETTERS, 2015, 584 :184-189
[43]   EFFECT OF AGMATINE ON 6-HYDROXYDOPAMINE INDUCED MEMORY IMPAIRMENT IN PARKINSON'S DISEASE IN RODENTS [J].
Kahale, V. P. ;
Shelat, P. ;
Mhaiskar, A. ;
Gaikwad, N. J. ;
Mundhada, D. R. .
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2015, 6 (11) :4743-4752
[44]   Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine [J].
Wang, Jian Yu ;
Yang, Jing Yu ;
Wang, Fang ;
Fu, Shi Yuan ;
Hou, Yue ;
Jiang, Bo ;
Ma, Jie ;
Song, Cui ;
Wu, Chun Fu .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
[45]   Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease [J].
Francardo, Veronica ;
Recchia, Alessandra ;
Popovic, Nataljia ;
Andersson, Daniel ;
Nissbrandt, Hans ;
Cenci, M. Angela .
NEUROBIOLOGY OF DISEASE, 2011, 42 (03) :327-340
[46]   Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat:: an animal model of Parkinson's disease [J].
Díaz, MR ;
Abdala, P ;
Barroso-Chinea, P ;
Obeso, J ;
González-Hernández, T .
BEHAVIOURAL BRAIN RESEARCH, 2001, 122 (01) :79-92
[47]   The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study [J].
Liu, Cheng-Tsung ;
Kao, Li-Ting ;
Shih, Jui-Hu ;
Chien, Wu-Chien ;
Chiu, Chuang-Hsin ;
Ma, Kuo-Hsing ;
Huang, Yuahn-Sieh ;
Cheng, Cheng-Yi ;
Shiue, Chyng-Yann ;
Li, I-Hsu .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 862
[48]   6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses [J].
Kupsch, Andreas ;
Schmidt, Werner ;
Gizatullina, Zemfira ;
Debska-Vielhaber, Grazyna ;
Voges, Juergen ;
Striggow, Frank ;
Panther, Patricia ;
Schwegler, Herbert ;
Heinze, Hans-Jochen ;
Vielhaber, Stefan ;
Gellerich, Frank Norbert .
JOURNAL OF NEURAL TRANSMISSION, 2014, 121 (10) :1245-1257
[49]   Propolis induces cardiac metabolism changes in 6-hydroxydopamine animal model: A dietary intervention as a potential cardioprotective approach in Parkinson's disease [J].
Goncalves, Valeria C. C. ;
Fonseca, Victor Silva da ;
Faria, Daniele de Paula ;
Izidoro, Mario Augusto ;
Berretta, Andresa Aparecida ;
Almeida, Antonio-Carlos G. de ;
Fonseca, Fernando Luiz Affonso ;
Scorza, Fulvio Alexandre ;
Scorza, Carla Alessandra .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[50]   Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease [J].
Schlachetzki, Johannes C. M. ;
Marxreiter, Franz ;
Regensburger, Martin ;
Kulinich, Anna ;
Winner, Beate ;
Winkler, Juergen .
RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 2014, 32 (04) :447-462